-
公开(公告)号：US5554513A
公开(公告)日：1996-09-10
申请号：US449447
申请日：1989-12-12
Applicant: Michel Revel , Asher Zilberstein
Inventor： Michel Revel , Asher Zilberstein
CPC classification number: C07K14/5412 , A61K38/215 , C07K14/565
Abstract: Human interferon-beta.sub.2.sbsb.A and interferon-beta.sub.2.sbsb.B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B, respectively. The sequence of IFN-.beta..sub.2.sbsb.A cDNA is established. These genes and cDNA have been cloned into mammalian cells with an SV40 early promoter sequence and such genomic clones are capable of producing IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B. The anti-viral activity of such recombinant IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B is demonstrated as well as other biological activity identifying them as human interferons.
Abstract translation: 通过重组DNA技术以纯化形式产生人干扰素-β2A和干扰素-β2B。 已经鉴定出分别编码IFN-β2A和IFN-β2B的两种分离的人类基因。 建立了IFN-β2AcDNA序列。 这些基因和cDNA已经用SV40早期启动子序列克隆到哺乳动物细胞中，并且这样的基因组克隆能够产生IFN-β2A和IFN-β2B。 证明了这种重组IFN-β2A和IFN-β2B的抗病毒活性以及将其识别为人类干扰素的其他生物学活性。
-
公开(公告)号：US5541312A
公开(公告)日：1996-07-30
申请号：US425934
申请日：1982-09-28
Applicant: Michel Revel , Pierre Tiollais
Inventor： Michel Revel , Pierre Tiollais
IPC: C12N15/09 , C07H21/02 , C07H21/04 , C07K14/54 , C07K14/565 , C12N15/00 , C12N15/22 , C12P19/34 , C12P21/00 , C12P21/02 , C12R1/19 , C12R1/91
CPC classification number: C07K14/5412 , C07K14/565
Abstract: The present invention .relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .sym.2 highly purified form, to the DNA coding for a polypeptide having interferon activity, insertable in a vector, such as plasmid pBR322, and also to human interferon .beta.1 in highly purified form, and human interferon .beta.2 in highly purified form.
Abstract translation: 本发明涉及分离含有人成纤维细胞中编码干扰素的核苷酸序列的遗传物质（DNA）的方法，其包括在暴露于干扰素诱导剂时培养产生干扰素的细胞，将其暴露于这种诱导物，从其中提取信使RNA 所述诱导细胞，纯化干扰素信使RNA，将信使RNA转录成DNA并将DNA克隆在合适的载体中。 优选的细胞是人二倍体包皮细胞。 本发明还涉及一种用于工程化细菌菌株以产生干扰素多肽的方法，其包括将克隆的干扰素DNA引入合适的载体载体中。 优选的载体载体是大肠杆菌。 本发明还涉及高度纯化形式的人干扰素与β1高度纯化形式的人干扰素的mRNA与（+）2高度纯化形式的人干扰素mRNA相关的编码多肽的DNA 具有干扰素活性，可插入载体，例如质粒pBR322，以及高度纯化形式的人干扰素β1，以及高度纯化形式的人干扰素β2。
-
23.发明授权Use of IL-6 for the treatment of chronic lymphocyte leukemia (CLL) and B-cell lymphomas 失效使用IL-6治疗慢性淋巴细胞白血病（CLL）和B细胞淋巴瘤
公开(公告)号：US5462731A
公开(公告)日：1995-10-31
申请号：US963313
申请日：1992-10-20
Applicant: Dan Aderka , Yasmin Maor , David Wallach , Michel Revel
Inventor： Dan Aderka , Yasmin Maor , David Wallach , Michel Revel
CPC classification number: A61K38/1793 , A61K38/204
Abstract: The use of interleukin-6 and/or salts, functional derivatives, muteins or active fractions thereof, in the treatment of chronic lymphocytic leukemia and B-cell lymphomas, as well as such use together with the soluble interleukin-6 receptor, to pharmaceutical compositions and to a method of treating chronic lymphocytic leukemia or B-cell lymphomas.
Abstract translation: 将白细胞介素-6和/或其盐，功能衍生物，突变蛋白或其活性成分用于治疗慢性淋巴细胞性白血病和B细胞淋巴瘤，以及与可溶性白细胞介素-6受体的这种用途用于药物组合物 以及治疗慢性淋巴细胞白血病或B细胞淋巴瘤的方法。
-
公开(公告)号：US5071742A
公开(公告)日：1991-12-10
申请号：US402700
申请日：1989-09-05
Applicant: David Mirelman , Leonard I. Garfinkel , Michael Giladi , Marion Huber , Carlos Gitler , Michel Revel , Shmuel Rozenblatt
Inventor： David Mirelman , Leonard I. Garfinkel , Michael Giladi , Marion Huber , Carlos Gitler , Michel Revel , Shmuel Rozenblatt
IPC: C12Q1/68
CPC classification number: C12Q1/6893 , Y10T436/143333
Abstract: An assay for the determination of the presence or absence of E. histolytica and for differentiation of these from other types of amoebae, as well as for the determination of whether the E. histolytica belongs to a symptomatic or asymptomatic strain, is carried out by means of a DNA-probe adapted to selectively hybridize only to the DNA of the amoeba tested. The probes being used selectively hybridize with, and thus diagnose the presence of, symptomatic (pathogenic) and asymptomatic (non-pathogenic) strains, respectively.
Abstract translation: 用于确定组织溶组织存在或不存在以及从其他类型的变形虫分化的测定以及用于确定是否属于有症状或无症状菌株的E.组织溶解度的测定是通过手段 的DNA探针，其适于仅选择性地与所测试的变形虫的DNA杂交。 使用的探针分别与有症状（致病性）和无症状（非致病性）菌株分别选择性杂交并因此诊断存在。
-
25.发明授权Constitutive production of human IFN-.beta.1 by mammalian cells transformed by the IFN-.beta.1 gene fused to an SV40 early promoter 失效通过与SV40早期启动子融合的IFN-β1基因转化的哺乳动物细胞组成生成人IFN-β1
公开(公告)号：US4808523A
公开(公告)日：1989-02-28
申请号：US669259
申请日：1984-11-07
Applicant: Michel Revel , Menachem Rubinstein
Inventor： Michel Revel , Menachem Rubinstein
IPC: C07K14/565 , C12N15/85 , C12P21/00 , C12N5/00 , C12N15/00
CPC classification number: C12N15/85 , C07K14/565 , Y10S435/811
Abstract: The invention concerns the production of the human fibroblast interferon, IFN-.beta.1 by cells of mammalian origin which are capable of constitutively expressing a DNA sequence encoding for IFN-.beta.1, producing the IFN and secreting it into the surrounding culture media.A specific embodiment of the invention comprises a methotrexate resistant chinese hamster ovary cell containing one or more pSVEIF molecules. The pSVEIF molecule contains a DNA sequence encoding for human INF-.beta.1 fused about 60 base pairs downstream from SV40 early start gene. The cell is capable of constitutively expressing the sequence encoding IFN-.beta.1, producing IFN-.beta.1 glycoprotein and secreting it into the surrounding medium.The invention also concerns methods of producing IFN-.beta. by culturing and growing the cells of the invention, and isolating and purifying the IFN-.beta.1 product.
Abstract translation: 本发明涉及由哺乳动物来源的细胞产生的人成纤维细胞干扰素IFN-β1，其能够组成型表达编码IFN-β1的DNA序列，产生IFN并将其分泌到周围的培养基中。 本发明的具体实施方案包括含有一个或多个pSVEIF分子的耐氨甲蝶呤中国仓鼠卵巢细胞。 pSVEIF分子含有编码融合SV40早期启动基因下游约60个碱基对的人INF-β1的DNA序列。 该细胞能够组成型表达编码IFN-β1的序列，产生IFN-β1糖蛋白并将其分泌到周围的培养基中。 本发明还涉及通过培养和生长本发明的细胞并分离和纯化IFN-β1产物来产生IFN-β的方法。
-
Patent Agency Ranking
26.发明申请Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns 有权产生胶质细胞和神经元细胞的方法及其用于治疗cns的医疗状况的方法公开(公告)号：US20100003751A1
公开(公告)日：2010-01-07
申请号：US12310495
申请日：2007-08-15
Applicant: Michel Revel , Judith Chebath , Michal Izrael , Rosalia Kaufman
Inventor： Michel Revel , Judith Chebath , Michal Izrael , Rosalia Kaufman
IPC: C12N5/08
CPC classification number: C12N5/0622 , A61K35/30 , C12N5/0619 , C12N2501/11 , C12N2501/115 , C12N2501/155 , C12N2501/385 , C12N2501/41 , C12N2506/02 , C12N2533/52 , C12N2533/90 , G01N33/5058
Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.
Abstract translation: 提供了一种产生神经和神经胶质细胞的方法。 该方法包括在诱导所述人类干细胞分化为神经和神经胶质细胞的条件下培养人类干细胞，所述条件包括视黄酸和能够下调骨形态发生蛋白活性的试剂的存在。
-
公开(公告)号：US20070237748A1
公开(公告)日：2007-10-11
申请号：US10560294
申请日：2004-06-13
Applicant: Michel Revel , Judith Chebath , Peter Lonai
Inventor： Michel Revel , Judith Chebath , Peter Lonai
CPC classification number: C12N5/0622 , A61K35/12 , C12N2500/25 , C12N2500/38 , C12N2500/44 , C12N2500/46 , C12N2500/90 , C12N2501/115 , C12N2501/23 , C12N2501/392 , C12N2501/91 , C12N2506/02 , C12N2509/00 , C12N2533/32 , C12N2533/52
Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.
Abstract translation: 本发明通常在神经疾病和病症领域中，特别是神经退行性疾病领域，其中神经的髓鞘被损失。 IL6R / IL6嵌合体用于促进来自胚胎干细胞的少突胶质细胞的形成，用于治疗神经变性疾病或创伤后神经损伤。
-
公开(公告)号：US5763210A
公开(公告)日：1998-06-09
申请号：US205358
申请日：1994-03-03
Applicant: Daniela Novick , Yves Mory , Dina G. Fischer , Michel Revel , Menachem Rubinstein
Inventor： Daniela Novick , Yves Mory , Dina G. Fischer , Michel Revel , Menachem Rubinstein
IPC: C12N1/21 , A61K38/00 , A61K38/21 , A61P37/00 , A61P43/00 , C07H21/04 , C07K1/22 , C07K14/00 , C07K14/52 , C07K14/555 , C07K14/57 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/28 , C12N1/11 , C12N15/12 , C12P21/08 , C12R1/19 , C12R1/91
CPC classification number: C07K14/7156 , C07K14/715 , C07K16/2866 , A61K38/00
Abstract: A cDNA encoding a new interferon-gamma (IFN-.gamma.)-binding protein is disclosed. Methods and products for the recombinant production of the protein are provided, and specific antibodies are also described.
Abstract translation: 公开了编码新的干扰素-γ（IFN-γ）结合蛋白的cDNA。 提供了重组生产蛋白质的方法和产物，并描述了特异性抗体。
-
29.发明授权IL-6 specific monoclonal antibodies, hybridomas therefor and methods of making and using same 失效IL-6特异性单克隆抗体，其杂交瘤及其制备和使用方法
公开(公告)号：US5618700A
公开(公告)日：1997-04-08
申请号：US436321
申请日：1989-11-14
Applicant: Daniela Novick , Michel Revel , Yves Mory , Menachem Rubinstein , Eran Hadas
Inventor： Daniela Novick , Michel Revel , Yves Mory , Menachem Rubinstein , Eran Hadas
CPC classification number: C07K14/31 , C07K14/5412 , C07K16/248 , A61K38/00 , C07K2319/00 , C07K2319/705 , C07K2319/75
Abstract: The hybridoma 34-1 (CNCM I-813) which produces anti-human IL-6 monoclonal antibody 34-1 is disclosed. Methods of producing the monoclonal antibody and methods for affinity purification of human IL-6 using monoclonal antibody 34-1 are also described.
Abstract translation: 公开了产生抗人IL-6单克隆抗体34-1的杂交瘤34-1（CNCM I-813）。 还描述了制备单克隆抗体的方法和使用单克隆抗体34-1亲和纯化人IL-6的方法。
-
公开(公告)号：US5554514A
公开(公告)日：1996-09-10
申请号：US657258
申请日：1991-02-19
Applicant: Michel Revel , Asher Zilberstein
Inventor： Michel Revel , Asher Zilberstein
CPC classification number: C07K14/5412 , A61K38/215 , C07K14/565
Abstract: Human interferon-beta.sub.2.sbsb.A and interferon-beta.sub.2.sbsb.B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B, respectively. The sequence of IFN-.beta..sub.2.sbsb.A cDNA is established. These genes and cDNA have been cloned into mammalian cells with an SV40 early promoter sequence and such genomic clones are capable of producing IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B. The antiviral activity of such recombinant IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B is demonstrated as well as other biological activity identifying them as human interferons.
Abstract translation: 通过重组DNA技术以纯化形式产生人干扰素-β2A和干扰素-β2B。 已经鉴定出分别编码IFN-β2A和IFN-β2B的两种分离的人类基因。 建立了IFN-β2AcDNA序列。 这些基因和cDNA已经用SV40早期启动子序列克隆到哺乳动物细胞中，并且这样的基因组克隆能够产生IFN-β2A和IFN-β2B。 证明了这种重组IFN-β2A和IFN-β2B的抗病毒活性以及将其识别为人类干扰素的其他生物学活性。
-
-
-
-
-
-
-
-
-
Search Results
46
records
(took 0.018 seconds)
